Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-024-04667-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Claire Miller und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Midazolam, Neoplasms, Cytochrome P-450 CYP3A, Drug Interactions. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Capivasertib, a potent, selective inhibitor of all three AKT serine/threonine kinase (AKT) isoforms, is being evaluated in phase 3 trials in advanced breast and prostate cancer. This study evaluated the drug–drug interaction risk of capivasertib with the cytochrome P450 3A substrate midazolam in previously treated adults with advanced solid tumors.
Methods
Patients received oral capivasertib 400 mg twice daily (BID) on an intermittent schedule (4 days on/3 days off) starting on day 2 of cycle 1 (29 days) and on day 1 of each 28-day cycle thereafter. In cycle 1 only, patients received oral midazolam (1 mg) on day 1 (alone), and days 8 and 12 (3rd day off and 4th day on capivasertib, respectively). Midazolam pharmacokinetics on days 8 and 12 were analyzed versus day 1. Capivasertib, with or without standard-of-care treatment, was continued in patients deemed likely to benefit. Safety and exploratory efficacy analyses were conducted.
Results
Capivasertib–midazolam coadministration increased midazolam exposure ( n = 21): geometric mean ratio (90% confidence interval) AUC inf and C max was 1.13 (0.97–1.32) and 1.15 (0.99–1.33) for day 8 versus day 1, and 1.75 (1.50–2.05) and 1.25 (1.08–1.46) for day 12 versus day 1. The capivasertib safety profile was manageable when administered with or without midazolam. Two patients had partial responses to treatment.
Conclusion
The up to 1.75-fold increase in midazolam exposure indicates capivasertib is a weak CYP3A inhibitor at 400 mg BID on an intermittent schedule. Capivasertib was well tolerated; exploratory efficacy analysis demonstrated evidence of clinical activity in this heavily pre-treated population. ClinicalTrials.gov: NCT04958226.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Late Developmental Oncology, AstraZeneca, Cambridge, UK.
- University of Colorado Cancer Center, Aurora, CO, USA.
- Mary Crowley Cancer Research Centers, Dallas, TX, USA.
- University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.
- UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Zitieren
APA
Miller, C., Sommavilla, R., O'Bryant, C. L., Barve, M., Dowlati, A., Luke, J. J., Khatun, M., Morris, T., & Cullberg, M. (2024). Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04667-3
Vancouver
Miller C, Sommavilla R, O'Bryant CL, Barve M, Dowlati A, Luke JJ, et al. Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04667-3
BibTeX
@article{Miller2024,
author = {Miller, Claire and Sommavilla, Roberto and O'Bryant, Cindy L and Barve, Minal and Dowlati, Afshin and Luke, Jason J and Khatun, Mahmuda and Morris, Thomas and Cullberg, Marie},
title = {Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04667-3}
}
EUVIMED